# US 2003/0229135 A1 · Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl)ethoxycarbonyl]-5-oxazolidine carboxylic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229135 A1
- Document ID: US20030229135A1
- Status: Published application
- Kind: A1
- Application number: 10/430,433
- Filed: 2003-05-07
- Published: 2003-12-11
- Earliest claimed: 2002-05-07
- Assignees: Dabur India Limited
- Inventors: Arun Prakash Sharma; Subrata Sarkar; Jyan Shankar Mahanti
- Web page: https://patentgrep.com/patent/US20030229135A1

## CPC

- C07D 263/04: having no double bonds between ring members or between ring members and non-ring members
- A61P 35/00: Antineoplastic agents
- C07D 305/14: condensed with carbocyclic rings or ring systems
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to a process for preparation of taxanes comprising subjecting 7,10-diprotected intermediates 7-O-(2-haloacyl) baccatin III 6c or 7,10-O-di-(2-haloacyl)-10-deacetylbaccatin III 6b to a step of coupling with (4S,5R)-3-[(2-alkyl/aryl-2-trialkylsilyl) ethoxy-carbonyl]-4-aryl-2-substituted-1,3-oxazolidine-5-carboxylic acid 1 in the presence of a condensation agent, an activating agent and an aromatic hydrocarbon to obtain 7-O-[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3(2-unsubstituted/substituted-2-trialkylsilyl)-ethoxycarbonyl-1,3-oxazolidinyl-5-carbonyl]baccatin III 7a or 7,10-di-O[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-unsubstituted/substituted-2-trialkylsilyl)ethoxy-carbonyl-1,3-oxazolidinyl-5-carbonyl]-10-deacetylbaccatin III 7b; treating the coupled products 7-O-[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-substituted-2-trialkylsilyl)ethoxy-carbonyl-1,3-oxazolidinyl-S-carbonyl]baccatin III 7a or 7,10-di-0-[2[(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-substituted-2-trialkylsilyl)ethoxycarbonyl-1,3-oxazolidinyl-5-carbonyl]-10-deacetylbaccatin III 7b with tetraalkylammonium halide in a haloalkane to obtain free amine of structure 8; treating free amine 8 with acid chloride or acid anhydride in the presence of a base in a heterogeneous phase to obtain the intermediates of structure 9; subjecting the intermediates of compound 9 to the deprotection of 2-haloacyl group under mild alkaline condition at −20 to +40° C. for 6-24 h in the presence of ammonia or aliphatic amines or aromatic amines or their combination to obtain paclitaxel or docetaxel.

## Claims

### Claim 1

A process for preparation of taxanes comprising
subjecting 7,10-diprotected intermediates 7-O-(2-haloacyl) baccatin III 6c or 7,10-O-di-(2-haloacyl)-10-deacetylbaccatin III 6b to a step of coupling with (4S,5R)-3-[(2-alkyl/aryl-2-trialkylsilyl) ethoxy-carbonyl]-4-aryl-2-substituted-1,3-oxazolidine-5-carboxylic acid 1 in the presence of a condensation agent, an activating agent and an aromatic hydrocarbon to obtain 7-O-[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3(2-unsubstituted/substituted-2-trialkylsilyl)-ethoxycarbonyl-1,3-oxazolidinyl-5-carbonyl]baccatin III 7a or 7,10-di-O[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-unsubstituted/substituted-2-trialkylsily l)ethoxy-carbonyl-1,3-oxazolidinyl-5-carbonyl]-10-deacetylbaccatin III 7b;
treating the coupled products 7-O-[2-(haloacyl)]-13-[(4S,5R)4-aryl-2-substituted-3-(2-substituted-2-trialkylsilyl)ethoxy-carbonyl-1,3-oxazolidinyl-5-carbonyl]baccatin III 7a or 7,10-di-O-[2(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-substituted-2-trialkylsilyl)ethoxycarbonyl-1,3-oxazolidinyl-5-carbonyl]-10-deacetylbaccatin III 7b with tetraalkylammonium halide in a haloalkane to obtain free amine of structure 8;
treating free amine 8 with acid chloride or acid anhydride in the presence of a base in a heterogeneous phase to obtain the intermediates of structure 9;
subjecting the intermediates of compound 9 to the deprotection of 2-haloacyl group under mild alkaline condition at −20 to +40° C. for 6-24 h in the presence of ammonia or aliphatic amines or aromatic amines or their combination to obtain paclitaxel or docetaxel.

### Claim 2

A process for the preparation of coupled product 7 comprising
subjecting 7,10-diprotected intermediates 7-O-(2-haloacyl) baccatin III 6c or 7,10-O-di-(2-haloacyl)10-deacetylbaccatin III 6b to a step of coupling with (4S,5R)-3-[(2-alkyl/aryl-2-trialkylsilyl) ethoxy-carbonyl]4-phenyl-2-substituted-1,3-oxazolidine-5-carboxylic acid 1 in the presence of a condensation agent, an activating agent and an aromatic hydrocarbon to obtain 7-O-[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3(2-unsubstituted/substituted-2-trialkylsilyl)-ethoxycarbonyl-1,3-oxazolidinyl-5-carbonyl]baccatin III 7a or 7,10-di-O[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-unsubstituted/substituted-2-trialkylsilyl)ethoxy-carbonyl-1,3-oxazoli-dinyl-5-carbonyl]-10-deacetylbaccatin III 7b.

### Claim 3 (depends on 1)

A process as claimed in claim 1 wherein said condensation agent is preferably dicyclohexylcarbodiimide and the activating agent is preferably am inopyridine most preferably 4-dimethyl-aminopyridine.

### Claim 4 (depends on 1)

A process as claimed in claim 1 wherein said aromatic hydrocarbon is preferably toluene.

### Claim 5 (depends on 1)

A process as claimed in claim 1 wherein the coupling reaction is carried out at a temperature between 0-100° C. and preferably at 40-80° C., most preferably at 60° C.

### Claim 6 (depends on 1)

A process as claimed in claim 1 wherein said tetraalkylammonium halide is tetrabutylammonium fluoride.

### Claim 7 (depends on 1)

A process as claimed in claim 1 wherein tetrabutylammonium fluoride in haloalkane, preferably dichloromethane is used.

### Claim 8 (depends on 1)

A process as claimed in claim 1 wherein deprotection of haloacyl group in the intermediate of compound 9 is carried out by treating compound 9 with 2:10 ammonia and pyridine preferably at 0-5° C., most preferably at 2° C. for 6-24 h, preferably for 10 h.

### Claim 9

A process for the preparation of oxazolidine carboxylic acid, of formula 1 comprising
condensing phenylisoserine with a (2-trialkylsilyl)ethyl haloformate in the presence of a base to obtain a N-protected isoserine, followed by converting the same into the corresponding methyl ester, treating the said ester with an alkoxyalkane or aryloxyalkane in the presence of a catalytic amount of arylsulfonic acid to obtain 5-oxazolidine carboxylic acid esters and hydrolysing the said esters in the presence of an alkali.

### Claim 10

The intermediate compound of formula 7.

### Claim 11 (depends on 10)

The compound 7a as claimed in claim 10 wherein the compound is 7-O-[2-(chloroacetyl)]-13-[(4S,5R) -2-p-methoxyphenyl-4-phenyl-3-(2-phenyl-2-trimethylsilyl-) ethoxycarbonyl]-1,3-oxazolidinyl-5-carbonyl]baccatin III.

### Claim 12 (depends on 10)

The compound 7b as claimed in claim 10 wherein the compound is 7,10-di-O-[2-(chloroacetyl)]-13-[(4S,5R)-2-p-methoxyphenyl-4-phenyl-3-(2-phenyl-2-trimethylsilyl)-ethoxycarbonyl]-1,3-oxazolidinyl-5-carbonyl]-10-deacetyl baccatin III.

### Claim 13 (depends on 10)

The compound 7c as claimed in claim 10 wherein the compound is 7-O-[2-chloroacetyl)]-13-[(4S,5R)-2-p-methoxyphenyl-4-phenyl-3-(2-trimethylsilyl)-ethoxycarbonyl]-1,3-oxazolidinyl-5-carbonyl]baccatin 111.

### Claim 14 (depends on 10)

The compound 7d as claimed in claim 10 wherein the compound is 7,10-di-O-[2-(chloroacetyl)]-13-[(4S,5R)-2-p-methoxyphenyl4-phenyl-3-(2-trimethylsilyl)ethoxycarbonyl-5-oxazolidinyl carbonyl]-1-deacetylbaccatin III.

### Claim 15

The oxazolidine carboxylic acid of formula 1.

### Claim 16

The compound of formula 8.

### Claim 17

The compound of formula 9.
